Neil Graham, MBBS, MD, MPH

Chief Development Officer

Dr. Neil Graham is a seasoned drug development leader and infectious diseases epidemiologist with a distinguished career spanning academia and global biopharma. He has driven antiviral and immunology programs from early research through late-stage development and global launch, with deep expertise in clinical strategy, regulatory execution, and portfolio leadership. At Kymera, he leads strategic and operational development across a pipeline of first-in-class programs leveraging targeted protein degradation to address multiple immuno-inflammatory diseases.

Throughout his career, Dr. Graham has contributed to several landmark therapeutic advances, including combination anti-HIV therapies at Glaxo Wellcome, Tibotec, and Trimeris; the first protease inhibitor for hepatitis C at Vertex; and, most notably, serving as Program Leader for the development of DUPIXENT® (dupilumab) at Regeneron – the first biologic targeting Th2-driven inflammation.

Earlier in his career, he was Associate Professor of Infectious Diseases Epidemiology at the Johns Hopkins Bloomberg School of Public Health and School of Medicine. He holds medical and postgraduate degrees from the University of Adelaide, including a doctorate in infectious diseases epidemiology and a Master of Public Health.